therapeutic action: amphotericin B therapy

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, which are particularly dangerous for people with weakened immune systems. The researchers found that while most hospitals can test fungal samples, not all have access to all necessary diagnostic tools, especially tests for detecting resistant fungi and identifying fungal co-infections. Many hospitals outsource their testing to other facilities, which can delay diagnosis and treatment, and some hospitals lack access to all recommended antifungal medications.

Read More »

Knowledge framework and emerging trends of invasive pulmonary fungal infection: A bibliometric analysis (2003–2023)

mycolabadmin

This study examined 20 years of scientific research on invasive lung fungal infections using bibliometric analysis. The research found that the United States leads in fungal infection research, with emerging focus areas including COVID-19-associated fungal infections and new diagnostic methods like metagenomic sequencing. The findings show that diagnosis remains challenging and requires improved detection methods, while treatment typically involves antifungal medications like voriconazole and amphotericin-B.

Read More »

China’s innovative national plan to combat fungal diseases and antifungal resistance

mycolabadmin

China has created a comprehensive national system to fight fungal infections and drug resistance. The system monitors fungal diseases across hundreds of hospitals throughout the country to track which infections are most common and which antifungal medicines are becoming less effective. Early findings show that many hospitals lack proper facilities for testing fungal infections, and some fungi are developing resistance to commonly used antifungal drugs, particularly fluconazole.

Read More »

China’s innovative national plan to combat fungal diseases and antifungal resistance

mycolabadmin

China has launched an ambitious national program to combat fungal diseases through a network of 868 hospitals across the country. Studies found that fungal infections are more common than previously thought, with concerning rates of drug resistance. The country is implementing surveillance systems, training healthcare workers, and carefully managing antifungal drug use to prevent further resistance development while improving patient outcomes.

Read More »
Scroll to Top